FDA Approves VYLEESI — Cosette Pharmaceuticals, Inc.

Cosette Pharmaceuticals received FDA approval for VYLEESI (bremelanotide acetate) on June 21, 2019, making it the first and only prescription therapy indicated for the treatment of hypoactive sexual desire disorder in premenopausal women. This clearance establishes a premium pricing precedent in the low-included $2 billion female hypoactive sexual desire disorder market, positioning the company to capitalize on a recognized unmet medical need.